Paige Announces Executive Leadership Appointments

Key Facts

Tweet this Dr. Moye most recently served as Chief Commercial Officer at Paige, where he led the company’s clinical sales and commercial strategy, including the U.S. launch of Paige Prostate, the first and only AI-based pathology product to receive FDA approval for in vitro diagnostic (IVD) use in detecting cancer in prostate biopsies.
“As we continue to deliver on the promise of AI in cancer diagnostics and drug development, I am driven by Paige’s unwavering commitment to bring products that can ultimately result in better patient care,” said Dr. Moye.
Prior to joining Paige, she served as Senior Vice President of Partnerships at Invitae by way of acquisition of ArcherDX, where she led global Companion Diagnostic partnerships with pharmaceutical companies to improve how cancer and genetically driven diseases are diagnosed and treated.
In 2021, Paige completed a $125 million Series C financing round to accelerate the transformation of digital pathology, announced several new partnerships with leading laboratories and scanner companies and deployed its digital pathology in global markets.